COLUMBIA, MD --  Cylex, a medical testing company, announced that it has obtained $18.4 in third round funding, bringing its total funding to $30.8 million.

The company's FDA-approved flagship product is a test that measures the health and vitality of a person's immune system from a drop of blood.  The test can tell physicians if a person is healthy enough to withstand treatments that are harsh on the body, such as chemotherapy.

Channel Medical Partners and Canaan Partners led the round and each assumed one board of directors seat.